Nitric oxide levels in exhaled air and inducible nitric oxide synthase immunolocalization in pulmonary sarcoidosis

Cytokines such as tumour necrosis factor-alpha and interferon gamma are associated with active pulmonary inflammation in sarcoidosis and they upregulate inducible nitric oxide synthase (iNOS). The objectives of this study were to examine iNOS upregulation in sarcoidosis by showing raised exhaled nitric oxide and increased iNOS activity in lung biopsy specimens of these patients utilizing immunohistochemistry. Exhaled NO was measured by a chemiluminescence analyser in 12 patients with newly diagnosed biopsy-proven sarcoidosis before and after 6 weeks of corticosteroid therapy. Lung biopsy specimens from these patients were subjected to immunohistochemical staining with a specific iNOS antibody. Exhaled NO was raised in newly diagnosed sarcoidosis (mean+/-SEM): 9.8+/-0.4 versus 4.1+/-0.2 parts per billion (ppb) in 21 healthy controls, p<0.001; and fell significantly after 6 weeks treatment with corticosteroids to 5.9+/-1.4 ppb; p<0.01. There was no correlation between exhaled NO and other markers of disease activity. Immunohistochemical staining demonstrated iNOS activity in respiratory epithelium and granulomas in patients with sarcoidosis. Exhaled nitric oxide is raised in patients with active pulmonary sarcoidosis and may be a result of inducible nitric oxide synthase upregulation. The fall in exhaled nitric oxide following corticosteroid therapy may reflect inhibition of inducible nitric oxide synthase in the respiratory epithelium and granulomas.

This article has been cited by other articles:

				D R Taylor, M W Pijnenburg, A D Smith, and J C D Jongste Exhaled nitric oxide measurements: clinical application and interpretation Thorax, September 1, 2006; 61(9): 817 - 827. [Abstract] [Full Text] [PDF]

				Y. Komohara, J. Hirahara, T. Horikawa, K. Kawamura, E. Kiyota, N. Sakashita, N. Araki, and M. Takeya AM-3K, an Anti-macrophage Antibody, Recognizes CD163, a Molecule Associated with an Anti-inflammatory Macrophage Phenotype J. Histochem. Cytochem., July 1, 2006; 54(7): 763 - 771. [Abstract] [Full Text] [PDF]

				M L Wilsher, W Fergusson, D Milne, and A U Wells Exhaled nitric oxide in sarcoidosis Thorax, November 1, 2005; 60(11): 967 - 970. [Abstract] [Full Text] [PDF]

				D. Ziora, K. Kaluska, and J. Kozielski An increase in exhaled nitric oxide is not associated with activity in pulmonary sarcoidosis Eur. Respir. J., October 1, 2004; 24(4): 609 - 614. [Abstract] [Full Text] [PDF]

				J. D. Lang, P. J. McArdle, P. J. O'Reilly, and S. Matalon Oxidant-Antioxidant Balance in Acute Lung Injury Chest, December 1, 2002; 122(6_suppl): 314S - 320S. [Abstract] [Full Text] [PDF]

				D.V. Pechkovsky, G. Zissel, C. Stamme, T. Goldmann, H. Ari Jaffe, M. Einhaus, C. Taube, H. Magnussen, M. Schlaak, and J. Muller-Quernheim Human alveolar epithelial cells induce nitric oxide synthase-2 expression in alveolar macrophages Eur. Respir. J., April 1, 2002; 19(4): 672 - 683. [Abstract] [Full Text] [PDF]

				S. A. KHARITONOV and P. J. BARNES Exhaled Markers of Pulmonary Disease Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1693 - 1722. [Full Text] [PDF]